Literature DB >> 19133603

First-line therapeutic strategies in metastatic colorectal cancer.

Janine M Davies1, Richard M Goldberg.   

Abstract

The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years. This review traces the evolution of treatment in this setting, including studies of single-agent vs combination treatment with 5-FU/leucovorin, irinotecan, oxaliplatin, and capecitabine, comparisons of simultaneous and sequential regimens, and the role of targeted agents such as bevacizumab, cetuximab, and panitumumab.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19133603

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


  16 in total

Review 1.  Pectin matrix as oral drug delivery vehicle for colon cancer treatment.

Authors:  Tin Wui Wong; Gaia Colombo; Fabio Sonvico
Journal:  AAPS PharmSciTech       Date:  2010-12-31       Impact factor: 3.246

Review 2.  Novel strategies for treating relapsed/refractory urothelial carcinoma.

Authors:  Gopa Iyer; Matthew I Milowsky; Dean F Bajorin
Journal:  Expert Rev Anticancer Ther       Date:  2010-12       Impact factor: 4.512

3.  Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1.

Authors:  Jia Lu; Xiangcang Ye; Fan Fan; Ling Xia; Rajat Bhattacharya; Seth Bellister; Federico Tozzi; Eric Sceusi; Yunfei Zhou; Isamu Tachibana; Dipen M Maru; David H Hawke; Janusz Rak; Sendurai A Mani; Patrick Zweidler-McKay; Lee M Ellis
Journal:  Cancer Cell       Date:  2013-01-31       Impact factor: 31.743

Review 4.  Assessment of neuropathic pain in cancer patients.

Authors:  Deborah T Blumenthal
Journal:  Curr Pain Headache Rep       Date:  2009-08

5.  miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.

Authors:  Yunfei Zhou; Guohui Wan; Riccardo Spizzo; Cristina Ivan; Rohit Mathur; Xiaoxiao Hu; Xiangcang Ye; Jia Lu; Fan Fan; Ling Xia; George A Calin; Lee M Ellis; Xiongbin Lu
Journal:  Mol Oncol       Date:  2013-10-08       Impact factor: 6.603

6.  ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.

Authors:  Yunfei Zhou; Lakshmi Reddy Bollu; Federico Tozzi; Xiangcang Ye; Rajat Bhattacharya; Guang Gao; Elizabeth Dupre; Ling Xia; Jia Lu; Fan Fan; Seth Bellister; Lee M Ellis; Zhang Weihua
Journal:  Mol Cancer Ther       Date:  2013-10-16       Impact factor: 6.261

7.  Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.

Authors:  Josef Thaler; Meinolf Karthaus; Laurent Mineur; Richard Greil; Henry Letocha; Ralf Hofheinz; Eva Fernebro; Erick Gamelin; Ana Baños; Claus-Henning Köhne
Journal:  BMC Cancer       Date:  2012-09-29       Impact factor: 4.430

8.  Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  J Transl Med       Date:  2010-12-16       Impact factor: 5.531

9.  APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.

Authors:  Russell D Petty; Leslie M Samuel; Graeme I Murray; Graham MacDonald; Terrence O'Kelly; Malcolm Loudon; Norman Binnie; Emad Aly; Aileen McKinlay; Weiguang Wang; Fiona Gilbert; Scot Semple; Elaina S R Collie-Duguid
Journal:  BMC Cancer       Date:  2009-12-11       Impact factor: 4.430

10.  The use of capecitabine in daily practice: a study on adherence and patients' experiences.

Authors:  Lonneke Timmers; Eleonora L Swart; Christel Clm Boons; Dirk Mangnus; Peter M van de Ven; Godefridus J Peters; Epie Boven; Jacqueline G Hugtenburg
Journal:  Patient Prefer Adherence       Date:  2012-10-19       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.